Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology has unveiled new preclinical data supporting the use of tipifarnib in treating HRAS/PI3K-dependent tumors, which account for up to 50% of head and neck squamous cell carcinoma (HNSCC) cases. The company plans to initiate a Phase 1/2 proof-of-concept study combining tipifarnib with a PI3Kα inhibitor in relapsed/refractory HNSCC. Current estimates suggest that 20% of HNSCC patients overexpress HRAS while 35% have PIK3CA mutations. Kura's ongoing AIM-HN trial focuses on HRAS mutant HNSCC, which affects 4-8% of patients.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that preliminary data from its KOMET-001 study will be presented at the 62nd ASH Annual Meeting on December 5, 2020. This ongoing trial evaluates the safety and efficacy of KO-539, an oral menin inhibitor for patients with relapsed/refractory acute myeloid leukemia (AML). Data will be available on the ASH website on November 5, 2020. The presentation aims to assess anti-leukemic activity in specific genetic subgroups, highlighting the potential of KO-539 in addressing high unmet medical needs.
Kura Oncology (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two virtual investor conferences. The events include a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET, and another at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 4:00 p.m. ET. Live webcasts will be accessible on Kura’s website, with archived replays available for 30 days. Kura is focused on precision medicines for cancer, with drug candidates targeting critical pathways in cancer treatment.
Kura Oncology announced the appointment of Stephen Dale, M.D., as the new Chief Medical Officer. Dr. Dale brings extensive experience from his previous role at Kyowa Kirin, focusing on oncology. His leadership is expected to enhance Kura's clinical development efforts, particularly for tipifarnib in HRAS-dependent head and neck cancers and KO-539 in acute myeloid leukemia.
Former acting CMO Bridget Martell will transition to Senior Scientific Advisor, continuing her contributions to Kura's strategic initiatives.
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference. CEO Troy Wilson is set to present on August 11, 2020, at 2:20 p.m. ET. The conference runs from August 11-12, 2020, and a live audio webcast will be available on the company’s website. Kura’s pipeline includes two drug candidates targeting cancer pathways, with tipifarnib in a pivotal trial for HRAS mutant head and neck cancer and KO-539 in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology, Inc. (Nasdaq: KURA) is set to release its second quarter 2020 financial results on August 6, 2020, after U.S. markets close. Management will hold a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Kura focuses on developing precision medicines for cancer with two promising drug candidates: tipifarnib, which targets HRAS mutant head and neck squamous cell carcinoma, and KO-539, aimed at treating acute myeloid leukemia.
Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Hematology & Oncology Forum on June 18, 2020. CEO Troy Wilson will engage in a fireside chat at 10:40 a.m. ET. The virtual event runs from June 18-19, and interested parties can access a live audio webcast via Kura's website, with an archived replay available for 30 days after the event.
Kura's pipeline includes drug candidates targeting cancer pathways, with its lead candidate being tipifarnib for HRAS mutant head and neck squamous cell carcinoma.
Kura Oncology, Inc. (Nasdaq: KURA) announced acceptance of three abstracts for tipifarnib presentation at the ASCO Virtual Scientific Program scheduled for May 29-31, 2020. Highlights include an oral presentation on the drug's single-agent activity in solid tumors with HRAS mutations, featuring data from the RUN-HN Phase 2 trial on HNSCC patients. Tipifarnib, a farnesyltransferase inhibitor, has Fast Track designation for treating HRAS mutant HNSCC, with prior studies indicating durable anti-cancer activity. The abstracts are accessible on ASCO's website.
Kura Oncology (Nasdaq: KURA) announced the successful closing of its public offering of 10,465,000 shares of common stock at $13.75 per share, raising approximately $143.9 million in gross proceeds. This includes the underwriters' full exercise of their option to purchase an additional 1,365,000 shares. The offering was conducted under an effective shelf registration statement filed with the SEC. Kura aims to advance its portfolio of precision medicines for cancer treatment, including its leading candidate, tipifarnib, for HRAS mutant head and neck cancer.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer, will present at the BofA Securities Virtual Healthcare Conference from May 12-14, 2020. CEO Troy Wilson is set to speak on May 12 at 3:40 p.m. ET. The company’s advanced drug candidate, tipifarnib, is undergoing a registration-directed trial for HRAS mutant head and neck squamous cell carcinoma. Another candidate, KO-539, is in a Phase 1/2A trial for relapsed/refractory acute myeloid leukemia. A live audio webcast of the presentation will be available on Kura's website.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
